Sensus HealthcareSRTS
SRTS
About: Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
Employees: 54
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1,600% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 1
1,068% more call options, than puts
Call options by funds: $222K | Put options by funds: $19K
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
50% more capital invested
Capital invested by funds: $22.6M [Q3] → $33.9M (+$11.3M) [Q4]
30% more funds holding
Funds holding: 50 [Q3] → 65 (+15) [Q4]
6.21% more ownership
Funds ownership: 23.71% [Q3] → 29.92% (+6.21%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
179%
upside
Avg. target
$12.50
191%
upside
High target
$13
202%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 33% 1-year accuracy 57 / 173 met price target | 179%upside $12 | Buy Reiterated | 4 Apr 2025 |
Lake Street Ben Haynor 44% 1-year accuracy 4 / 9 met price target | 202%upside $13 | Buy Maintained | 11 Mar 2025 |
Financial journalist opinion
Based on 3 articles about SRTS published over the past 30 days
Positive
Zacks Investment Research
5 days ago
Is Sensus Healthcare (SRTS) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Negative
Zacks Investment Research
1 week ago
Sensus Healthcare, Inc. (SRTS) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $4.69, marking a +1.3% move from the previous day.
Negative
Zacks Investment Research
3 weeks ago
Sensus Healthcare, Inc. (SRTS) Increases Despite Market Slip: Here's What You Need to Know
Sensus Healthcare, Inc. (SRTS) reachead $4.48 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.
Neutral
Zacks Investment Research
1 month ago
Sensus Healthcare, Inc. (SRTS) Rises As Market Takes a Dip: Key Facts
Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.69, moving +1.08% from the previous trading session.
Positive
Zacks Investment Research
1 month ago
Here's Why Sensus Healthcare, Inc. (SRTS) Gained But Lagged the Market Today
Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.78, moving +0.84% from the previous trading session.
Neutral
Business Wire
1 month ago
Sensus Healthcare to Participate in the 37th Annual ROTH Conference
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be participating in Roth Capital's 37th Annual ROTH Conference, being held March 17-18 in Dana Point, California. Management will be holding one-on-one meetings with registered investors during the conference. Registered attendees.
Neutral
Zacks Investment Research
1 month ago
Brokers Suggest Investing in Sensus Healthcare (SRTS): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Neutral
Business Wire
1 month ago
Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be showcasing its full line of commercial Superficial Radiotherapy (SRT) products including the SRT-100®, SRT-100+ and SRT-100 Vision™ systems, along with several innovative pre-commercial products, at the 2025 American Academy of.
Neutral
Business Wire
1 month ago
Sensus Healthcare Announces Publication of Study at Tri Service Military Hospital in Taiwan Demonstrating Efficacy of SRT-100® in Preventing Keloid Recurrence
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the publication of a study titled "Keloid Excision With Primary Closure Combined With Superficial Radiation Therapy (SRT-100)" in the Annals of Plastic Surgery. The single-site, retrospective study evaluated the clinical outcomes of combin.
Neutral
Business Wire
2 months ago
Sensus Healthcare Buys Back Shares
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the company has resumed purchasing shares of its common stock in open-market transactions under a $3.0 million share repurchase program approved by its Board of Directors and announced in August 2023. “We are implementing this program.
Charts implemented using Lightweight Charts™